Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Lenz G. J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14. No abstract available.
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.
Blood. 2017 Feb 15. pii: blood-2016-12-758599. doi: 10.1182/blood-2016-12-758599. [Epub ahead of print]
Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Lange J, Lenz G, Burkhardt B. Expert Rev Hematol. 2016 Dec 26:1-13. doi: 10.1080/17474086.2017.1271318. [Epub ahead of print]
The molecular pathogenesis of mantle cell lymphoma.Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G. Leuk Lymphoma. 2016 Nov 28:1-8. [Epub ahead of print]
B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G. Blood. 2016 Nov 18. pii: blood-2016-05-718775. [Epub ahead of print]
Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M. Bone Marrow Transplant. 2016 Nov;51(11):1441-1448. doi: 10.1038/bmt.2016.156.
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE. Oncotarget. 2016 Oct 11. doi: 10.18632/oncotarget.12559. [Epub ahead of print]
Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. Vogt N, Heß K, Bialek R, Buerke B, Brüggemann M, Topp MS, Groth C, Berdel WE, Lenz G, Stelljes M. Ann Hematol. 2017 Jan;96(1):151-153. doi: 10.1007/s00277-016-2837-1. No abstract available.
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE. Haematologica. 2016 Oct;101(10):1208-1215. Epub 2016 Jul 28.
Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. Gätjen M, Brand F, Grau M, Gerlach K, Kettritz R, Westermann J, Anagnostopoulos I, Lenz P, Lenz G, Höpken UE, Rehm A. Cancer Res. 2016 Sep 15;76(18):5253-65. doi: 10.1158/0008-5472.CAN-15-3486. Epub 2016 Aug 3.
Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt ML, Mah N, Weilemann A, Grau M, Gröning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Müller-Tidow C, Rosenbauer F. EMBO J. 2016 Aug 29. pii: e201693927. [Epub ahead of print]
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann ML, Kreher S, Köchert K, Krappmann D, Klapper W, Hummel M, Wenzel SS, Lenz G, Janz M, Dörken B, Siebert R, Mathas S. Leukemia. 2016 Aug 19. doi: 10.1038/leu.2016.238. [Epub ahead of print]
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Keßler T, Kerkhoff A, Lenz G, Berdel WE. Cancer Res Treat. 2016 Jul 12. doi: 10.4143/crt.2016.110. [Epub ahead of print]
Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years). Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M. Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.156. [Epub ahead of print]
Novel NF-κB regulator in ABC DLBCL. Lenz G. Blood. 2016 Jun 9;127(23):2785-6. doi: 10.1182/blood-2016-03-704254. No abstract available.
Approaching resistance to ibrutinib in diffuse large B-cell lymphoma. Erdmann T, Lenz G. Leuk Lymphoma. 2016 Jun;57(6):1254-5. doi: 10.3109/10428194.2015.1136742. Epub 2016 Apr 11. No abstract available.
Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas. Bognar MK, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott G, Lenz G, Hauck SM, Krappmann D. Oncogene. 2016 Jan 18. doi: 10.1038/onc.2015.493. [Epub ahead of print]
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Juilland M, Gonzalez M, Erdmann T, Banz Y, Jevnikar Z, Hailfinger S, Tzankov A, Grau M, Lenz G, Novak U, Thome M. Blood. 2016 Jan 8. pii: blood-2015-07-655647

Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation. Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G, Ruland J. Proc Natl Acad Sci U S A. 2015 Dec 14. pii: 201507459. [Epub ahead of print]

Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE. Bone Marrow Transplant. 2015 Nov 9. doi: 10.1038/bmt.2015.266. [Epub ahead of print] No abstract available.

XI. Management of paediatric and adult Non-Hodgkin-Lymphoma: What lessons can each teach the other? Burkardt B andLenz G.Hematol Oncol. 2015 Jun;33 Suppl 1:62-6. doi: 10.1002/hon.2219.
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and its Therapeutic Implications.  Lenz G.Cancers (Basel). 2015 May 22;7(2):811-822.

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.

Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G. Blood. 2015 Jan 1;125(1):124-32. doi: 10.1182/blood-2014-08-594507. Epub 2014 Oct 30.

Activity-Based Probes for Detection of Active MALT1 Paracaspase in Immune Cells and Lymphomas.

Eitelhuber AC, Vosyka O, Nagel D, Bognar M, Lenze D, Lammens K, Schlauderer F, Hlahla D, Hopfner KP, Lenz G, Hummel M, Verhelst SH, Krappmann D. Chem Biol. 2015 Jan 22;22(1):129-38. doi: 10.1016/j.chembiol.2014.10.021. Epub 2014 Dec 31.

 

Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.

Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C,Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F. Nat Med. 2014 Dec;20(12):1401-9. doi: 10.1038/nm.3740. Epub 2014 Nov 24.

 

Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.

Kreher S, Bouhlel MA, Cauchy P, Lamprecht B, Li S, Grau M, Hummel F, Köchert K, Anagnostopoulos I, Jöhrens K, Hummel M, Hiscott J, Wenzel SS, Lenz P, Schneider M, Küppers R, Scheidereit C, Giefing M, Siebert R, Rajewsky K, Lenz G, Cockerill PN, Janz M, Dörken B, Bonifer C, Mathas S. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4513-22. doi: 10.1073/pnas.1406985111. Epub 2014 Oct 6.

 

Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase.

Hailfinger S,Lenz G, Thome M.Curr Opin Chem Biol. 2014 Dec;23:47-55. doi: 10.1016/j.cbpa.2014.09.025. Epub 2014 Oct 4.

 

Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.

Heinig K, Gätjen M, Grau M, Stache V, Anagnostopoulos I, Gerlach K, Niesner RA, Cseresnyes Z, Hauser AE, Lenz P, Hehlgans T, Brink R, Westermann J, Dörken B, Lipp M, Lenz G, Rehm A, Höpken UE. Cancer Discov. 2014 Dec;4(12):1448-65. doi: 10.1158/2159-8290.CD-14-0096. Epub 2014 Sep 24.

 

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: Tumor-induced immunosuppression and a possible role for NF-κB.

Flörcken A, Grau M, Wolf A, Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J. Int J Cancer.2014 Sep 20. doi: 10.1002/ijc.29230.

 

Waldenstrom macroglobulinemia: genetics dictates clinical course.

Lenz G. Blood. 2014 May 1;123(18):2750-1. doi: 10.1182/blood-2014-03-558973.

 

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G*, Stegmeier F*.Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.

*Equally contributing last and corresponsing author

 

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O'Riain C, O'Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J. Nat Genet. 2014 Feb;46(2):176-81. doi: 10.1038/ng.2856. Epub 2013 Dec 22.

 

PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma.

Pfeifer M, Lenz G. Cell Cycle. 2013 Nov 1;12(21):3347-8. doi: 10.4161/cc.26575. Epub 2013 Sep 23. No abstract available.

 

Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface.

Cabalzar K, Pelzer C, Wolf A, Lenz G, Iwaszkiewicz J, Zoete V, Hailfinger S, Thome M. PLoS One. 2013 Aug 19;8(8):e72051. doi: 10.1371/journal.pone.0072051. eCollection 2013.

 

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.

Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A, Hummel M, Dörken B, Scheidereit C, Janz M, Lenz P, Thome M, Lenz G. Blood. 2013 Sep 26;122(13):2242-50. doi: 10.1182/blood-2013-06-508028. Epub 2013 Jul 18.

 

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.

Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dirnhofer S, Lenz P, Hummel M, Tzankov A, Lenz G. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420-5. doi: 10.1073/pnas.1305656110. Epub 2013 Jul 9.

 

The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.

Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M. Nat Immunol. 2013 Apr;14(4):337-45. doi: 10.1038/ni.2540. Epub 2013 Feb 17.

 

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.

Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, Deeb G, Dörken B, Thome M, Lenz P, Dirnhofer S, Hernandez-Ilizaliturri FJ, Tzankov A, Lenz G. Leukemia. 2013 Jun;27(6):1381-90. doi: 10.1038/leu.2012.367.

 

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, Dörken B, Lenz P, Lenz G, Schendel DJ, Krappmann D. Cancer Cell. 2012 Dec 11;22(6):825-37. doi: 10.1016/j.ccr.2012.11.002.

 

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD. J Clin Oncol.2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

 

Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.

Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M. Ann Hematol. 2012 Nov;91(11):1765-72. doi: 10.1007/s00277-012-1534-y. Epub 2012 Aug 29.

 

New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.

Frick M, Dörken B, Lenz G. Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8. Review.

 

The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.

Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, Wright G, Staudt LM, Zhao Y, McKeithan TW, Chan WC, Fu K. Leukemia. 2012 May;26(5):1064-72. doi: 10.1038/leu.2011.305.

 

The molecular biology of diffuse large B-cell lymphoma.

Frick M, Dörken B, Lenz G. Ther Adv Hematol. 2011 Dec;2(6):369-79. doi: 10.1177/2040620711419001.

 

Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.

Jing H, Kase J, Dörr JR, Milanovic M, Lenze D, Grau M, Beuster G, Ji S, Reimann M, Lenz P, Hummel M, Dörken B, Lenz G, Scheidereit C, Schmitt CA, Lee S. Genes Dev. 2011 Oct 15;25(20):2137-46. doi: 10.1101/gad.17620611. Epub 2011 Oct 6.

 

Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.

Hailfinger S, Nogai H, Pelzer C, Jaworski M, Cabalzar K, Charton JE, Guzzardi M, Décaillet C, Grau M, Dörken B, Lenz P, Lenz G, Thome M. Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14596-601. doi: 10.1073/pnas.1105020108. Epub 2011 Aug 22

 

The use of microarray technologies in mantle cell lymphoma.

Ratsch BA, Grau M, Dörken B, Lenz P, Lenz G. Semin Hematol.2011 Jul;48(3):166-71. doi: 10.1053/j.seminhematol.2011.03.007. Review.

 

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.

Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, González-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Braziel R, Rosenwald A, Lenz G, Wright G, Jaffe ES, Staudt L, Jares P, López-Guillermo A, Campo E. Haematologica. 2011 Jul;96(7):996-1001. doi: 10.3324/haematol.2010.037408. Epub 2011 May 5.

 

Pathogenesis of non-Hodgkin's lymphoma.

Nogai H, Dörken B, Lenz G. J Clin Oncol. 2011 May 10;29(14):1803-11. doi: 10.1200/JCO.2010.33.3252. Epub 2011 Apr 11. Review.

 

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, Lenz P, Waters NJ, Schuler W, Dörken B, Yao YM, Warmuth M,Lenz G, Stegmeier F. Cancer Res.2011 Apr 1;71(7):2643-53. doi: 10.1158/0008-5472.CAN-10-2525. Epub 2011 Feb 15.

 

Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M. Oncogene. 2011 Jul 14;30(28):3198-206. doi: 10.1038/onc.2011.79.

 

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

Kloo B, Nagel D, Pfeifer M, Grau M, Düwel M, Vincendeau M, Dörken B, Lenz P, Lenz G, Krappmann D. Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):272-7. doi: 10.1073/pnas.1008969108. Epub 2010 Dec 20.

 

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD. Am J Clin Pathol. 2011 Jan;135(1):54-61. doi: 10.1309/AJCPJX4BJV9NLQHY.

 

Cooperative epigenetic modulation by cancer amplicon genes.

Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. Cancer Cell.2010 Dec 14;18(6):590-605. doi: 10.1016/j.ccr.2010.11.013.

 

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, Vose JM,Lenz G, Staudt LM, Chan WC, Weisenburger DD. J Clin Oncol. 2011 Jan 10;29(2):200-7. doi: 10.1200/JCO.2010.30.0368. Epub 2010 Dec 6.

 

Targeting the microenvironment.

Gribben J, Rosenwald A, Gascoyne R, Lenz G. Leuk Lymphoma. 2010 Aug;51 Suppl 1:34-40. doi: 10.3109/10428194.2010.500072. Review.

 

Prognostic biomarkers in malignant lymphomas.

Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Leuk Lymphoma.2010 Aug;51 Suppl 1:11-9. doi: 10.3109/10428194.2010.500046. Review.

 

Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.

Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, Xiao W, Braziel RM, Rimsza LM, Chan WC, Weisenburger DD, Delabie J, Jaffe ES, Gascoyne RD, Dave SS, Mueller-Hermelink HK, Staudt LM, Ott G, Beà S, Rosenwald A. Blood. 2010 Aug 12;116(6):953-61. doi: 10.1182/blood-2010-01-263806. Epub 2010 Apr 26.

 

Aggressive lymphomas.

Lenz G, Staudt LM.N Engl J Med. 2010 Apr 15;362(15):1417-29. doi: 10.1056/NEJMra0807082. Review. No abstract available.

 

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. N Engl J Med. 2010 Mar 11;362(10):875-85. doi: 10.1056/NEJMoa0905680.

 

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE*, Ngo VN*, Lenz G*, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.

*Authors contributed equally

 

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, Penas EM, Dierlamm J, Chan WC, Staudt LM, Thome M. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19946-51. doi: 10.1073/pnas.0907511106. Epub 2009 Nov 6. Erratum in: Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2677.

 

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC. Clin Cancer Res. 2009 Sep 1;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113. Epub 2009 Aug 25.

 

Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.

Bidère N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE, Lenz G, Anderson DE, Arnoult D, Vazquez A, Sakai K, Zhang J, Meng Z, Veenstra TD, Staudt LM, Lenardo MJ.

Nature. 2009 Mar 5;458(7234):92-6. doi: 10.1038/nature07613. Epub 2008 Dec 31.

 

Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.

Lam LT, Davis RE, Ngo VN,Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, Staudt LM. Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20798-803. doi: 10.1073/pnas.0806491106. Epub 2008 Dec 22.

 

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. doi: 10.1073/pnas.0804295105. Epub 2008 Sep 2.

 

Stromal gene signatures in large-B-cell lymphomas.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.

 

Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma.

Christopeit M, Lenz G, Forstpointner R, Bartelheim K, Kühnbach R, Naujoks K, Schalhorn A. Chemotherapy. 2008;54(4):309-14. doi: 10.1159/000151352. Epub 2008 Aug 14.

 

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Science. 2008 Mar 21;319(5870):1676-9. doi: 10.1126/science.1153629. Epub 2008 Mar 6.

 

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM. Blood. 2008 Apr 1;111(7):3701-13. Epub 2007 Dec 26.

 

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM. Cancer Cell. 2007 Aug;12(2):115-30.

 

Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.

Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM. J Exp Med. 2007 Mar 19;204(3):633-43. Epub 2007 Mar 12.

 

Current management of follicular lymphomas.

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Br J Haematol.2007 Jan;136(2):191-202. Epub 2006 Oct 31. Review.

 

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG. Blood. 2006 Sep 1;108(5):1469-77. Epub 2006 Apr 25.

 

A loss-of-function RNA interference screen for molecular targets in cancer.

Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, Lam LT, Dave S, Yang L, Powell J, Staudt LM. Nature. 2006 May 4;441(7089):106-10. Epub 2006 Mar 29.

 

Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?

Lenz G, Dreyling M. Nat Clin Pract Oncol. 2005 Feb;2(2):72-3. No abstract available.

Treatment strategies in follicular lymphomas: current status and future perspectives.

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M. J Clin Oncol. 2005 Sep 10;23(26):6394-9.

 

Treatment strategies in follicular lymphomas: current status and future perspectives.

Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M. J Clin Oncol.2005 Sep 10;23(26):6394-9. Review.

 

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. J Clin Oncol.2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24.

 

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.

Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W. J Clin Oncol.2004 Dec 15;22(24):4926-33.

 

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Dreyling M,Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9.

 

The role of fludarabine in the treatment of follicular and mantle cell lymphoma.

Lenz G, Hiddemann W, Dreyling M. Cancer. 2004 Sep 1;101(5):883-93. Review.

 

Current strategies in the treatment of advanced stage mantle cell lymphoma.

Lenz G, Dreyling M, Unterhalt M, Hiddemann W. Dtsch Med Wochenschr. 2004 Nov 5;129(45):2429-33.

 

Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia.

Lenz G, Hutter G, Hiddemann W, Dreyling M. Ann Hematol. 2004 Oct;83(10):628-33. Epub 2004 Aug 12.

 

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 1;104(9):2667-74. Epub 2004 Jul 6.

 

Erythroblastic synartesis in a patient initially diagnosed with myelodysplastic syndrome.

Bacher U, Lenz G, Haferlach T, Loeffler H, Moosmann N, Hiddemann W, Ostermann H. Ann Hematol. 2005 Apr;84(4):272-3.

 

Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications.

Hacker U, Lenz G, Brehm G, Müller-Höcker J, Schalhorn A, Hiddemann W. Anticancer Res. 2003 Nov-Dec;23(6D):4973-6.

 

Mantle cell lymphoma: established therapeutic options and future directions.

Lenz G, Dreyling M, Hiddemann W. Ann Hematol. 2004 Feb;83(2):71-7.

 

Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine.

Lenz G, Golf A, Rüdiger T, Hiddemann W, Haferlach T. Blood. 2003 Nov 1;102(9):3457-8. No abstract available.

 

Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.

Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W. Anticancer Drugs. 2003 Oct;14(9):731-3.

 

Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.

Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL. Bone Marrow Transplant. 2001 Dec;28(12):1105-9.

Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells.

Theil J, Laumen H, Marafioti T, Hummel M, Lenz G, Wirth T, Stein H. Blood. 2001 May 15;97(10):3191-6.

 

Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin.

Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, Stein H. Blood. 1999 Nov 1;94(9):3108-13.